Prevalence of the GFI1-36N SNP in Multiple Myeloma Patients and Its Impact on the Prognosis.
Gfi1
SNP variant
multiple myeloma
prevalance
prognosis
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
12
08
2021
accepted:
01
10
2021
entrez:
11
11
2021
pubmed:
12
11
2021
medline:
12
11
2021
Statut:
epublish
Résumé
Transcription factor Growth Factor Independence 1 (GFI1) regulates the expression of genes important for survival, proliferation and differentiation of hematopoietic cells. A single nucleotide polymorphism (SNP) variant of GFI1 (GFI1-36N: serine replaced by asparagine at position 36), has a prevalence of 5-7% among healthy Caucasians and 10-15% in patients with myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML) predisposing GFI-36N carriers to these diseases. Since GFI1 is implicated in B cell maturation and plasma cell (PC) development, we examined its prevalence in patients with multiple myeloma (MM), a haematological malignancy characterized by expansion of clonal PCs. Strikingly, as in MDS and AML, we found that the GFI1-36N had a higher prevalence among MM patients compared to the controls. In subgroup analyses, GFI1-36N correlates to a shorter overall survival of MM patients characterized by the presence of t(4;14) translocation and gain of 1q21 (≤3 copies). MM patients carrying gain of 1q21 (≥3 copies) demonstrated poor progression free survival. Furthermore, gene expression analysis implicated a role for GFI1-36N in epigenetic regulation and metabolism, potentially promoting the initiation and progression of MM.
Identifiants
pubmed: 34760702
doi: 10.3389/fonc.2021.757664
pmc: PMC8574071
doi:
Types de publication
Journal Article
Langues
eng
Pagination
757664Informations de copyright
Copyright © 2021 Khandanpour, Eisfeld, Nimmagadda, Raab, Weinhold, Seckinger, Hose, Jauch, Försti, Hemminki, Hielscher, Hummel, Lenz, Goldschmidt and Huhn.
Déclaration de conflit d'intérêts
Author MH was employed by company Roche Diagnostics GmbH. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Exp Hematol. 2016 Jul;44(7):590-595.e1
pubmed: 27080012
Immunity. 2009 Oct 16;31(4):576-86
pubmed: 19818654
J Hematol Oncol. 2019 Jun 26;12(1):65
pubmed: 31242924
Nat Genet. 2013 Oct;45(10):1221-1225
pubmed: 23955597
Exp Hematol. 2016 Aug;44(8):713-726.e14
pubmed: 27216773
Leukemia. 2019 Jan;33(1):110-121
pubmed: 29925903
Leukemia. 2018 Jan;32(1):102-110
pubmed: 28584253
Front Oncol. 2019 Aug 27;9:824
pubmed: 31508375
Commun Biol. 2019 Mar 4;2:89
pubmed: 30854481
Leukemia. 2015 Aug;29(8):1721-9
pubmed: 25787915
Cancer Cell. 2017 Jul 10;32(1):88-100.e6
pubmed: 28669490
N Engl J Med. 2011 Mar 17;364(11):1046-60
pubmed: 21410373
Nat Commun. 2018 Sep 13;9(1):3707
pubmed: 30213928
Nucleic Acids Res. 2012 Sep 1;40(17):e133
pubmed: 22638577
Lancet. 2015 May 30;385(9983):2197-208
pubmed: 25540889
Leukemia. 2020 Mar;34(3):697-708
pubmed: 31913320
Leukemia. 2014 Feb;28(2):269-77
pubmed: 23974982
Nat Genet. 2011 Nov 27;44(1):58-61
pubmed: 22120009
Blood. 2006 Sep 1;108(5):1724-32
pubmed: 16705089
Blood. 2011 Dec 22;118(26):6871-80
pubmed: 22042697